ClinicalTrials.gg
CompletedNCT03732807ALLEGRO-2b/3Updated Feb 24, 2022Results posted

PF-06651600 for the Treatment of Alopecia Areata

A Phase 2/3 interventional study of PF-06651600 Induction Dose and PF-06651600 Maintenance Dose #1 in Alopecia Areata, sponsored by Pfizer. Completed at 155 sites in 18 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2022-02-24.

Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
718
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Alopecia Areata by Pfizer — 4 open to participants now, 8 under way, 4 of them phase 3. Alopecia Areata · Pfizer.

Enrollment
2nd of 10
718 · median 175
Started
2018
the only one that year
Phase 2/3
Only one
of the 17
Registered
2nd of 17
by date

Among the 17 studies in Alopecia Areata by Pfizer, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2018, is the only one in phase 2/3, and was the 2nd registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

4 of the 17 studies in Alopecia Areata by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Alopecia Areata by Pfizer, or all of them as a file.
02

Study summary

This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). This is a dose-ranging study, investigating 5 different dosing regimens. It will be double-blinded, meaning that the sponsor, the study doctors, the staff, and the patients will not know whether a patient is on active study drug (or the dose) or placebo.

03

Conditions studied

  • Alopecia Areata

Keywords

  • Alopecia
  • Alopecia totalis
  • Alopecia universalis
  • Patchy hair loss
  • Diffuse hair loss
  • Hair loss
  • Hair disease
  • PF-06651600
  • Ritlecitinib
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of alopecia areata with no other cause of hair loss
  • ≥50% hair loss of the scalp, including alopecia totalis and alopecia universalis, without evidence of terminal hair regrowth within 6 months
  • Current episode of hair loss ≤10 years

Exclusion criteria

Exclusion Criteria:

  • Other types of alopecia or other diseases that can cause hair loss
  • Other scalp diseases that could interfere with assessment of hair loss/regrowth
  • Subjects with shaved heads must not enter the study until hair has grown back \& is considered stable by the investigator
  • Any previous use of any Janus kinase (JAK) inhibitor
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
718 participants (actual)

Study arms

  • Experimental
    Sequence A

    Induction dose given once daily (QD) for 4 weeks followed by maintenance dose #1 given QD for 44 weeks

    Drug: PF-06651600 Induction Dose · Drug: PF-06651600 Maintenance Dose #1

  • Experimental
    Sequence B

    Induction dose given QD for 4 weeks followed by maintenance dose #2 given QD for 44 weeks

    Drug: PF-06651600 Induction Dose · Drug: PF-06651600 Maintenance Dose #2

  • Experimental
    Sequence C

    Maintenance dose #1 given QD for 48 weeks

    Drug: PF-06651600 Maintenance Dose #1

  • Experimental
    Sequence D

    Maintenance dose #2 given QD for 48 weeks

    Drug: PF-06651600 Maintenance Dose #2

  • Experimental
    Sequence E

    Maintenance dose #3 given QD for 48 weeks

    Drug: PF-06651600 Maintenance Dose #3

  • Experimental
    Sequence F

    Placebo given QD for 24 weeks followed by induction dose given QD for 4 weeks then maintenance dose #1 given QD for 20 weeks

    Drug: PF-06651600 Induction Dose · Drug: PF-06651600 Maintenance Dose #1 · Drug: Placebo

  • Experimental
    Sequence G

    Placebo given QD for 24 weeks followed by maintenance dose #1 given QD for 24 weeks

    Drug: PF-06651600 Maintenance Dose #1 · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24

    SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score less than or equal to (\<=) 20 at week 24 were reported.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 4

    SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score \<= 10 at week 24 were reported.

    Time frame: Week 24

  2. Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 1

    SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score \<= 10 at week 24 were reported.

    Time frame: Week 24

  3. Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 24

    PGI-C is a self-administered questionnaire to evaluate the improvement or worsening of participant's AA as compared to the start of the study. PGI-C was assessed on a 7-point Likert scale ranged from 1 (greatly improved) to 7 (greatly worsened). Categories were defined based on the PGI-C scores as follows: 1=greatly improved, 2=moderately improved, 3=slightly improved, 4=not changed, 5=slightly worsened, 6=moderately worsened and 7=greatly worsened.

    Time frame: Week 24

  4. Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 20 at Week 24: Maximum Effect (Emax) Model

    The exposure response of Ritlecitinib (PF-06651600) on the regrowth of scalp hair was characterized using a Bayesian three-parameter hyperbolic Emax model for the SALT score \<=20 at Week 24 with an additional term for effect of loading dose. In Emax exposure-response model the response function was the log odds of the percentage of participants with response based on SALT \<=20 at Week 24, which was fit on the logistic scale and then back-transformed to percentage. The effect of loading dose is included as fixed factor in the model. The variable that represents loading dose has values of 1 for groups 200/50 mg once daily and 200/30 mg once daily and of 0 for the remaining groups. SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease.

    Time frame: Week 24

  5. Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 10 at Week 24: Maximum Effect (Emax) Model

    The exposure response of Ritlecitinib (PF-06651600) on the regrowth of scalp hair was characterized using a Bayesian three-parameter hyperbolic Emax model for the SALT score \<=10 at Week 24 with an additional term for effect of loading dose. In Emax exposure-response model the response function was the log odds of the percentage of participants with response based on SALT \<=10 at Week 24, which was fit on the logistic scale and then back-transformed to percentage. The effect of loading dose is included as fixed factor in the model. The variable that represents loading dose has values of 1 for groups 200/50 mg once daily and 200/30 mg once daily and of 0 for the remaining groups. SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease.

    Time frame: Week 24

  6. Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48

    SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease.

    Time frame: Week 4, 8, 12, 18, 28, 34, 40, and 48

  7. Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48

    SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score \<=10 were reported.

    Time frame: Week 4, 8, 12, 18, 28, 34, 40, and 48

  8. Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48

    SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. A SALT 75 response was a 75% or greater reduction from baseline in SALT score.

    Time frame: Week 4, 8, 12, 18, 24, 28, 34, 40, and 48

  9. Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24

    SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. Baseline was defined as pre-dose on Day 1.

    Time frame: Baseline (Day 1), Week 4, 8, 12, 18, and 24

  10. Change From Baseline in SALT Score at Week 28, 34, 40, and 48

    SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. Baseline was defined as pre-dose on Day 1.

    Time frame: Baseline (Day 1), Week 28, 34, 40, and 48

  11. Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48

    EBA is a numeric rating scale developed to characterize eyebrow hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal), where, 0= no eyebrow, 1=minimal eyebrow, 2=moderate eyebrow and 3= normal eyebrow, where higher scores represent less hair loss of eyebrows.

    Time frame: Week 4, 8, 12, 18, 24, 28, 34, 40, and 48

  12. Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48

    ELA is a numeric rating scale developed to characterize eyelash hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal), where, 0=no eyelash, 1=minimal eyelash, 2=moderate eyelash and 3=normal eyelash, where higher scores represent less hair loss of eyelash.

    Time frame: Week 4, 8, 12, 18, 24, 28, 34, 40, and 48

  13. Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48

    PGI-C is a self-administered questionnaire to evaluate the improvement or worsening of participant's AA as compared to the start of the study. PGI-C was assessed on a 7-point Likert scale ranged from 1 (greatly improved) to 7 (greatly worsened). Categories were defined based on the PGI-C scores as follows: 1=greatly improved, 2=moderately improved, 3=slightly improved, 4=not changed, 5=slightly worsened, 6=moderately worsened and 7=greatly worsened.

    Time frame: Week 4, 8, 12, 18, 24, 34, 40, and 48

  14. Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations

    AAPPO scale is 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over past week. Items 1-4 assessed current hair loss, eyebrow loss, eyelash loss and body hair loss and were analyzed separately on scale of 0-4, with 0 ='no hair loss' and 4='complete hair loss'. Items 5-8 assessed emotional symptoms. Response choices on these items were scored from 0 ='never' to 4='always'. Items 9-11 assessed activity limitations. Response choices on these items were scored from 0='not at all' to 4='completely'. Change from baseline in AAPPO emotional symptoms sub score were calculated as mean of items 5-8 and ranged from 0(never) to 4(always), where higher scores indicated more emotional symptoms. Change from baseline in AAPPO activity limitations sub score was calculated as mean of items 9-11 and ranged from 0(not at all) to 4(completely), where higher scores indicated more activity limitations. Baseline was defined as pre-dose on Day 1.

    Time frame: Baseline (Day 1), Week 4, 8, 12, 18, and 24

  15. Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations

    AAPPO scale is 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over past week. Items 1-4 assessed current hair loss, eyebrow loss, eyelash loss and body hair loss and were analyzed separately on scale of 0-4, with 0 ='no hair loss' and 4='complete hair loss'. Items 5-8 assessed emotional symptoms. Response choices on these items were scored from 0 ='never' to 4='always'. Items 9-11 assessed activity limitations. Response choices on these items were scored from 0='not at all' to 4='completely'. Change from baseline in AAPPO emotional symptoms sub score were calculated as mean of items 5-8 and ranged from 0(never) to 4(always), where higher scores indicated more emotional symptoms. Change from baseline in AAPPO activity limitations sub score was calculated as mean of items 9-11 and ranged from 0(not at all) to 4(completely), where higher scores indicated more activity limitations. Baseline was defined as pre-dose on Day 1.

    Time frame: Baseline (Day 1), Week 34, 40, and 48

  16. Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48

    AAPPO scale is a 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over the past week. Items 1-4 were to assess the current hair loss, eyebrow loss, eyelash loss and body hair loss and were analyzed separately on a scale of 0-4, with 0 ='no hair loss' and 4='complete hair loss', where higher scores indicated more hair loss.

    Time frame: Week 4, 8, 12, 18, 24, 34, 40, and 48

Other outcomes

  1. Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24

    HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for depression subscale; higher score indicating greater severity of depression symptoms. Baseline was defined as pre-dose on Day 1.

    Time frame: Baseline (Day 1), Week 4, 8, 12, and 24

  2. Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48

    HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for depression subscale; higher score indicating greater severity of depression symptoms. Baseline was defined as pre-dose on Day 1.

    Time frame: Baseline (Day 1), Week 48

  3. Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24

    HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for anxiety subscale; higher score indicating greater severity of anxiety symptoms. Baseline was defined as pre-dose on Day 1.

    Time frame: Baseline (Day 1), Week 4, 8, 12, and 24

  4. Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48

    HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for anxiety subscale; higher score indicating greater severity of anxiety symptoms. Baseline was defined as pre-dose on Day 1.

    Time frame: Baseline (Day 1), Week 48

  5. Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48

    HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for depression subscale; higher score indicating greater severity of depression symptoms.

    Time frame: Week 4, 8, 12, 24 and 48

  6. Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48

    HADS is a validated 14-item PRO measure used to assessed states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for anxiety subscale; higher score indicating greater severity of anxiety symptoms.

    Time frame: Week 4, 8, 12, 24 and 48

07

Results

Posted Feb 24, 2022

Participant flow

Treatment Period (up to Week 24)
Participant flow — Treatment Period (up to Week 24)
MilestoneRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mgPlacebo, Ritlecitinib (PF-06651600) 50 mg
Started132130130132636566
Completed122124121117586361
Not completed106915525
Withdrew: Adverse event3024201
Withdrew: Lost to follow-up1012100
Withdrew: Physician decision0125001
Withdrew: Pregnancy1000101
Withdrew: Protocol violation1100000
Withdrew: Withdrawal by subject4444112
Withdrew: Lack of efficacy0000010
Treatment Extension (Week 25 up to 48)
Participant flow — Treatment Extension (Week 25 up to 48)
MilestoneRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mgPlacebo, Ritlecitinib (PF-06651600) 50 mg
Started113111108106495957
Completed10710010397445653
Not completed61159534
Withdrew: Adverse event0221002
Withdrew: Lack of efficacy2103301
Withdrew: Lost to follow-up0021120
Withdrew: Non-compliant with study drug0100000
Withdrew: Physician decision0101100
Withdrew: Withdrawal by subject3211011
Withdrew: Other1402000

Outcome measures

PrimaryPercentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24

SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score less than or equal to (\<=) 20 at week 24 were reported.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24
Percentage of participantsRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo
Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 2430.65 (22.53 to 38.76)22.31 (14.90 to 29.73)23.39 (15.94 to 30.84)14.29 (8.00 to 20.57)1.69 (0.00 to 4.99)1.54 (0.00 to 3.65)
Statistical analysis
  • Ritlecitinib (PF-06651600) 200 mg Then 50 mg vs Placebo · Miettinen and Nurminen method · p = <0.000001 · Estimate of difference: 29.11 · 95% CI 21.17 to 37.91
  • Ritlecitinib (PF-06651600) 200 mg Then 30 mg vs Placebo · Miettinen and Nurminen method · p = <0.000001 · Estimate of difference: 20.78 · 95% CI 13.65 to 29.18
  • Ritlecitinib (PF-06651600) 50 mg vs Placebo · Miettinen and Nurminen method · p = <0.000001 · Estimate of difference: 21.85 · 95% CI 14.65 to 30.23
  • Ritlecitinib (PF-06651600) 30 mg vs Placebo · Miettinen and Nurminen method · p = 0.000154 · Estimate of difference: 12.75 · 95% CI 6.69 to 20.36
SecondaryPercentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 4

SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score \<= 10 at week 24 were reported.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 4
Percentage of participantsRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo
Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 421.2912.8713.4210.621.651.54
Statistical analysis
  • Ritlecitinib (PF-06651600) 200 mg Then 50 mg vs Placebo · Miettinen and Nurminen method · p = <0.000001 · Estimate of difference: 19.75 · 95% CI 11.91 to 27.59
  • Ritlecitinib (PF-06651600) 200 mg Then 30 mg vs Placebo · Miettinen and Nurminen method · p = 0.000526 · Estimate of difference: 11.33 · 95% CI 4.93 to 17.74
  • Ritlecitinib (PF-06651600) 50 mg vs Placebo · Miettinen and Nurminen method · p = 0.000311 · Estimate of difference: 11.88 · 95% CI 5.42 to 18.33
  • Ritlecitinib (PF-06651600) 30 mg vs Placebo · Miettinen and Nurminen method · p = 0.002922 · Estimate of difference: 9.09 · 95% CI 3.10 to 15.07
SecondaryPercentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 1

SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score \<= 10 at week 24 were reported.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 1
Percentage of participantsRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo
Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 121.77 (14.51 to 29.04)13.22 (7.19 to 19.26)13.71 (7.66 to 19.76)10.92 (5.32 to 16.53)1.69 (0.00 to 4.99)1.54 (0.00 to 3.65)
Statistical analysis
  • Ritlecitinib (PF-06651600) 200 mg Then 50 mg vs Placebo · Miettinen and Nurminen method · p = <0.000001 · Estimate of difference: 20.24 · 95% CI 13.23 to 28.49
  • Ritlecitinib (PF-06651600) 200 mg Then 30 mg vs Placebo · Miettinen and Nurminen method · p = 0.000337 · Estimate of difference: 11.68 · 95% CI 5.82 to 19.07
  • Ritlecitinib (PF-06651600) 50 mg vs Placebo · Miettinen and Nurminen method · p = 0.000228 · Estimate of difference: 12.17 · 95% CI 6.27 to 19.53
  • Ritlecitinib (PF-06651600) 30 mg vs Placebo · Miettinen and Nurminen method · p = 0.001875 · Estimate of difference: 9.39 · 95% CI 3.86 to 16.46
SecondaryPercentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 24

PGI-C is a self-administered questionnaire to evaluate the improvement or worsening of participant's AA as compared to the start of the study. PGI-C was assessed on a 7-point Likert scale ranged from 1 (greatly improved) to 7 (greatly worsened). Categories were defined based on the PGI-C scores as follows: 1=greatly improved, 2=moderately improved, 3=slightly improved, 4=not changed, 5=slightly worsened, 6=moderately worsened and 7=greatly worsened.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 24
Percentage of participantsRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo
Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 2452.1945.4049.1741.9511.369.23
Statistical analysis
  • Ritlecitinib (PF-06651600) 200 mg Then 50 mg vs Placebo · Miettinen and Nurminen method · p = <0.000001 · Estimate of difference: 42.96 · 95% CI 31.68 to 54.25
  • Ritlecitinib (PF-06651600) 200 mg Then 30 mg vs Placebo · Miettinen and Nurminen method · p = <0.000001 · Estimate of difference: 36.18 · 95% CI 25.22 to 47.14
  • Ritlecitinib (PF-06651600) 50 mg vs Placebo · Miettinen and Nurminen method · p = <0.000001 · Estimate of difference: 39.96 · 95% CI 28.85 to 51.06
  • Ritlecitinib (PF-06651600) 30 mg vs Placebo · Miettinen and Nurminen method · p = <0.000001 · Estimate of difference: 32.72 · 95% CI 21.95 to 43.50
SecondaryExposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 20 at Week 24: Maximum Effect (Emax) Model

The exposure response of Ritlecitinib (PF-06651600) on the regrowth of scalp hair was characterized using a Bayesian three-parameter hyperbolic Emax model for the SALT score \<=20 at Week 24 with an additional term for effect of loading dose. In Emax exposure-response model the response function was the log odds of the percentage of participants with response based on SALT \<=20 at Week 24, which was fit on the logistic scale and then back-transformed to percentage. The effect of loading dose is included as fixed factor in the model. The variable that represents loading dose has values of 1 for groups 200/50 mg once daily and 200/30 mg once daily and of 0 for the remaining groups. SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 20 at Week 24: Maximum Effect (Emax) Model
Percentage of participantsRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo
Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 20 at Week 24: Maximum Effect (Emax) Model32.3720.5722.5213.584.811.63
SecondaryExposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 10 at Week 24: Maximum Effect (Emax) Model

The exposure response of Ritlecitinib (PF-06651600) on the regrowth of scalp hair was characterized using a Bayesian three-parameter hyperbolic Emax model for the SALT score \<=10 at Week 24 with an additional term for effect of loading dose. In Emax exposure-response model the response function was the log odds of the percentage of participants with response based on SALT \<=10 at Week 24, which was fit on the logistic scale and then back-transformed to percentage. The effect of loading dose is included as fixed factor in the model. The variable that represents loading dose has values of 1 for groups 200/50 mg once daily and 200/30 mg once daily and of 0 for the remaining groups. SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 10 at Week 24: Maximum Effect (Emax) Model
Percentage of participantsRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo
Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 10 at Week 24: Maximum Effect (Emax) Model21.2913.7614.439.023.881.66
SecondaryPercentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48

SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease.

Time frame:
Week 4, 8, 12, 18, 28, 34, 40, and 48
Reported as:
Number · Percentage of participants
Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48
Percentage of participantsRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mgPlacebo, Ritlecitinib (PF-06651600) 50 mg
Week 40.78 (0.00 to 2.29)0.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)
Week 85.47 (1.53 to 9.41)4.13 (0.59 to 7.68)2.46 (0.00 to 5.21)0.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)
Week 1211.90 (6.25 to 17.56)8.87 (3.87 to 13.88)6.35 (2.09 to 10.61)3.28 (0.12 to 6.44)3.39 (0.00 to 8.01)1.64 (0.00 to 4.83)1.59 (0.00 to 4.67)
Week 1819.83 (12.73 to 26.94)13.22 (7.19 to 19.26)13.11 (7.12 to 19.10)9.40 (4.11 to 14.69)3.33 (0.00 to 7.88)1.67 (0.00 to 4.91)1.61 (0.00 to 4.75)
Week 2834.17 (25.68 to 42.65)23.53 (15.91 to 31.15)26.05 (18.16 to 33.94)20.49 (13.33 to 27.65)5.00 (0.00 to 10.51)1.75 (0.00 to 5.16)6.35 (0.33 to 12.37)
Week 3438.40 (29.87 to 46.93)27.64 (19.74 to 35.55)33.87 (25.54 to 42.20)28.69 (20.66 to 36.71)5.08 (0.00 to 10.69)19.67 (9.70 to 29.65)9.23 (2.19 to 16.27)
Week 4039.06 (30.61 to 47.51)33.33 (25.00 to 41.66)39.34 (30.68 to 48.01)30.00 (21.80 to 38.20)6.78 (0.36 to 13.19)23.08 (12.83 to 33.32)15.38 (6.61 to 24.16)
Week 4839.53 (31.10 to 47.97)34.43 (26.00 to 42.86)43.20 (34.52 to 51.88)31.15 (22.93 to 39.37)9.84 (2.36 to 17.31)33.85 (22.34 to 45.35)18.75 (9.19 to 28.31)
SecondaryPercentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48

SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score \<=10 were reported.

Time frame:
Week 4, 8, 12, 18, 28, 34, 40, and 48
Reported as:
Number · Percentage of participants
Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48
Percentage of participantsRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mgPlacebo, Ritlecitinib (PF-06651600) 50 mg
Week 40.78 (0.00 to 2.29)0.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)
Week 82.34 (0.00 to 4.96)0.83 (0.00 to 2.44)0.82 (0.00 to 2.42)0.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)
Week 126.35 (2.09 to 10.61)5.65 (1.58 to 9.71)5.56 (1.56 to 9.56)0.82 (0.00 to 2.42)1.69 (0.00 to 4.99)0.00 (NA to NA)1.59 (0.00 to 4.67)
Week 1812.40 (6.52 to 18.27)7.44 (2.76 to 12.11)6.56 (2.16 to 10.95)5.13 (1.13 to 9.12)1.67 (0.00 to 4.91)1.67 (0.00 to 4.91)1.61 (0.00 to 4.75)
Week 2829.17 (21.03 to 37.30)16.81 (10.09 to 23.53)18.49 (11.51 to 25.46)16.39 (9.82 to 22.96)3.33 (0.00 to 7.88)1.75 (0.00 to 5.16)3.17 (0.00 to 7.50)
Week 3430.40 (22.34 to 38.46)18.70 (11.81 to 25.59)23.39 (15.94 to 30.84)22.13 (14.76 to 29.50)3.39 (0.00 to 8.01)13.11 (4.64 to 21.59)4.62 (0.00 to 9.72)
Week 4031.25 (23.22 to 39.28)25.20 (17.53 to 32.88)27.05 (19.17 to 34.93)25.00 (17.25 to 32.75)3.39 (0.00 to 8.01)18.46 (9.03 to 27.89)9.23 (2.19 to 16.27)
Week 4833.33 (25.20 to 41.47)27.87 (19.91 to 35.82)31.20 (23.08 to 39.32)25.41 (17.68 to 33.14)6.56 (0.35 to 12.77)24.62 (14.14 to 35.09)14.06 (5.55 to 22.58)
SecondaryPercentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48

SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. A SALT 75 response was a 75% or greater reduction from baseline in SALT score.

Time frame:
Week 4, 8, 12, 18, 24, 28, 34, 40, and 48
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48
Percentage of participantsRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mgPlacebo, Ritlecitinib (PF-06651600) 50 mg
Week 40.78 (0.00 to 2.29)0.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)0.00 (NA to NA)
Week 84.69 (1.03 to 8.35)3.31 (0.12 to 6.49)1.64 (0.00 to 3.89)0.83 (0.00 to 2.44)0.00 (NA to NA)1.59 (0.00 to 4.67)0.00 (NA to NA)
Week 1211.90 (6.25 to 17.56)8.06 (3.27 to 12.86)6.35 (2.09 to 10.61)2.46 (0.00 to 5.21)1.69 (0.00 to 4.99)1.64 (0.00 to 4.83)1.59 (0.00 to 4.67)
Week 1820.66 (13.45 to 27.88)14.88 (8.54 to 21.22)9.84 (4.55 to 15.12)11.11 (5.42 to 16.81)1.67 (0.00 to 4.91)1.67 (0.00 to 4.91)1.61 (0.00 to 4.75)
Week 2431.45 (23.28 to 39.62)20.66 (13.45 to 27.88)22.58 (15.22 to 29.94)13.45 (7.32 to 19.57)1.69 (0.00 to 4.99)1.54 (0.00 to 4.53)3.08 (0.00 to 7.28)
Week 2834.17 (25.68 to 42.65)24.37 (16.66 to 32.08)27.73 (19.69 to 35.77)21.31 (14.04 to 28.58)5.00 (0.00 to 10.51)3.51 (0.00 to 8.29)4.76 (0.00 to 10.02)
Week 3438.40 (29.87 to 46.93)32.52 (24.24 to 40.80)38.71 (30.14 to 47.28)28.69 (20.66 to 36.71)5.08 (0.00 to 10.69)21.31 (11.03 to 31.59)10.77 (3.23 to 18.31)
Week 4039.84 (31.36 to 48.33)34.96 (26.53 to 43.39)42.62 (33.85 to 51.40)30.00 (21.80 to 38.20)5.08 (0.00 to 10.69)23.08 (12.83 to 33.32)15.38 (6.61 to 24.16)
Week 4839.53 (31.10 to 47.97)36.07 (27.54 to 44.59)46.40 (37.66 to 55.14)31.15 (22.93 to 39.37)9.84 (2.36 to 17.31)32.31 (20.94 to 43.68)21.88 (11.75 to 32.00)
SecondaryChange From Baseline in SALT Score at Week 4, 8, 12, 18, and 24

SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. Baseline was defined as pre-dose on Day 1.

Time frame:
Baseline (Day 1), Week 4, 8, 12, 18, and 24
Reported as:
Least squares mean · Units on a scale
Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24
Units on a scaleRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo
Change at Week 4-2.3 (-3.64 to -1.01)-2.7 (-4.03 to -1.35)-1.8 (-3.16 to -0.50)-1.3 (-2.60 to 0.06)-1.3 (-3.19 to 0.69)-0.9 (-2.17 to 0.46)
Change at Week 8-12.8 (-15.56 to -10.05)-12.5 (-15.28 to -9.71)-6.3 (-9.10 to -3.50)-5.0 (-7.82 to -2.21)-1.7 (-5.74 to 2.34)-1.2 (-3.99 to 1.50)
Change at Week 12-22.7 (-26.47 to -18.97)-20.1 (-23.87 to -16.30)-12.4 (-16.18 to -8.61)-10.3 (-14.11 to -6.47)-3.5 (-9.00 to 1.98)-2.4 (-6.12 to 1.35)
Change at Week 18-31.2 (-35.63 to -26.83)-25.0 (-29.41 to -20.55)-22.5 (-26.94 to -18.07)-17.5 (-22.02 to -13.02)-2.4 (-8.87 to 3.97)-3.9 (-8.31 to 0.43)
Change at Week 24-36.5 (-41.54 to -31.53)-29.2 (-34.21 to -24.15)-33.3 (-38.33 to -28.25)-23.6 (-28.72 to -18.45)-4.2 (-11.50 to 3.13)-5.1 (-10.03 to -0.13)
SecondaryChange From Baseline in SALT Score at Week 28, 34, 40, and 48

SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. Baseline was defined as pre-dose on Day 1.

Time frame:
Baseline (Day 1), Week 28, 34, 40, and 48
Reported as:
Mean · Units on a scale
Change From Baseline in SALT Score at Week 28, 34, 40, and 48
Units on a scaleRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mgPlacebo, Ritlecitinib (PF-06651600) 50 mg
Baseline90.3 ± 15.0590.5 ± 14.2890.3 ± 14.6990.0 ± 15.0788.3 ± 16.8794.4 ± 9.3191.5 ± 13.22
Change at Week 28-44.1 ± 36.35-33.3 ± 33.85-36.1 ± 33.42-29.2 ± 32.56-5.6 ± 23.15-11.5 ± 22.75-5.0 ± 18.51
Change at Week 34-48.2 ± 36.16-35.5 ± 35.50-43.6 ± 34.35-33.5 ± 35.01-7.6 ± 23.61-27.5 ± 32.78-12.6 ± 24.47
Change at Week 40-49.3 ± 36.11-38.5 ± 37.14-46.9 ± 35.68-35.9 ± 35.90-11.4 ± 26.01-36.5 ± 34.56-23.0 ± 30.64
Change at Week 48-49.4 ± 36.09-40.5 ± 37.27-48.9 ± 36.63-40.1 ± 35.87-13.3 ± 30.13-46.3 ± 35.51-32.2 ± 32.39
SecondaryPercentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48

EBA is a numeric rating scale developed to characterize eyebrow hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal), where, 0= no eyebrow, 1=minimal eyebrow, 2=moderate eyebrow and 3= normal eyebrow, where higher scores represent less hair loss of eyebrows.

Time frame:
Week 4, 8, 12, 18, 24, 28, 34, 40, and 48
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48
Percentage of participantsRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mgPlacebo, Ritlecitinib (PF-06651600) 50 mg
Week 41.87 (0.00 to 4.44)2.88 (0.00 to 6.10)0.00 (NA to NA)0.93 (0.00 to 2.76)1.96 (0.00 to 5.77)0.00 (NA to NA)3.85 (0.00 to 9.07)
Week 810.28 (4.53 to 16.03)13.86 (7.12 to 20.60)2.97 (0.00 to 6.28)4.90 (0.71 to 9.09)3.85 (0.00 to 9.07)3.77 (0.00 to 8.90)0.00 (NA to NA)
Week 1222.86 (14.83 to 30.89)17.48 (10.14 to 24.81)9.62 (3.95 to 15.28)7.62 (2.54 to 12.69)6.25 (0.00 to 13.10)0.00 (NA to NA)4.00 (0.00 to 9.43)
Week 1829.70 (20.79 to 38.61)18.81 (11.19 to 26.43)17.82 (10.36 to 25.29)12.87 (6.34 to 19.40)10.20 (1.73 to 18.68)0.00 (NA to NA)8.16 (0.50 to 15.83)
Week 2433.98 (24.83 to 43.13)25.49 (17.03 to 33.95)29.00 (20.11 to 37.89)16.67 (9.43 to 23.90)8.33 (0.51 to 16.15)3.64 (0.00 to 8.58)5.77 (0.00 to 12.11)
Week 2837.00 (27.54 to 46.46)29.00 (20.11 to 37.89)27.27 (18.50 to 36.05)24.76 (16.51 to 33.02)12.24 (3.07 to 21.42)4.17 (0.00 to 9.82)6.00 (0.00 to 12.58)
Week 3441.35 (31.88 to 50.81)30.77 (21.90 to 39.64)34.65 (25.37 to 43.93)31.43 (22.55 to 40.31)14.58 (4.60 to 24.57)15.69 (5.71 to 25.67)13.46 (4.18 to 22.74)
Week 4043.40 (33.96 to 52.83)30.39 (21.47 to 39.32)39.00 (29.44 to 48.56)33.65 (24.57 to 42.74)16.00 (5.84 to 26.16)20.00 (9.43 to 30.57)26.92 (14.87 to 38.98)
Week 4842.99 (33.61 to 52.37)32.67 (23.53 to 41.82)43.56 (33.89 to 53.23)33.33 (24.32 to 42.35)16.00 (5.84 to 26.16)30.91 (18.70 to 43.12)31.37 (18.64 to 44.11)
SecondaryPercentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48

ELA is a numeric rating scale developed to characterize eyelash hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal), where, 0=no eyelash, 1=minimal eyelash, 2=moderate eyelash and 3=normal eyelash, where higher scores represent less hair loss of eyelash.

Time frame:
Week 4, 8, 12, 18, 24, 28, 34, 40, and 48
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48
Percentage of participantsRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mgPlacebo, Ritlecitinib (PF-06651600) 50 mg
Week 43.03 (0.00 to 6.41)1.08 (0.00 to 3.17)5.38 (0.79 to 9.96)1.03 (0.00 to 3.04)4.55 (0.00 to 10.70)2.04 (0.00 to 6.00)0.00 (NA to NA)
Week 89.09 (3.43 to 14.75)4.44 (0.19 to 8.70)8.79 (2.97 to 14.61)4.35 (0.18 to 8.51)2.22 (0.00 to 6.53)2.04 (0.00 to 6.00)0.00 (NA to NA)
Week 1216.49 (9.11 to 23.88)10.99 (4.56 to 17.41)11.70 (5.20 to 18.20)7.37 (2.11 to 12.62)4.76 (0.00 to 11.20)0.00 (NA to NA)0.00 (NA to NA)
Week 1825.53 (16.72 to 34.35)20.00 (11.74 to 28.26)20.00 (11.74 to 28.26)12.09 (5.39 to 18.79)6.98 (0.00 to 14.59)2.17 (0.00 to 6.39)0.00 (NA to NA)
Week 2430.21 (21.02 to 39.39)21.35 (12.84 to 29.86)28.89 (19.52 to 38.25)26.09 (17.11 to 35.06)4.88 (0.00 to 11.47)9.80 (1.64 to 17.97)0.00 (NA to NA)
Week 2829.79 (20.54 to 39.03)25.00 (15.95 to 34.05)36.78 (26.65 to 46.91)24.21 (15.60 to 32.82)4.76 (0.00 to 11.20)6.82 (0.00 to 14.27)4.55 (0.00 to 10.70)
Week 3434.02 (24.59 to 43.45)26.37 (17.32 to 35.43)38.89 (28.82 to 48.96)26.32 (17.46 to 35.17)7.32 (0.00 to 15.29)16.67 (6.12 to 27.21)6.52 (0.00 to 13.66)
Week 4039.80 (30.10 to 49.49)28.09 (18.75 to 37.43)38.20 (28.11 to 48.30)27.66 (18.62 to 36.70)18.60 (6.97 to 30.24)25.49 (13.53 to 37.45)17.39 (6.44 to 28.34)
Week 4838.38 (28.80 to 47.96)29.55 (20.01 to 39.08)40.00 (29.88 to 50.12)30.53 (21.27 to 39.79)20.93 (8.77 to 33.09)37.25 (23.99 to 50.52)35.56 (21.57 to 49.54)
SecondaryPercentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48

PGI-C is a self-administered questionnaire to evaluate the improvement or worsening of participant's AA as compared to the start of the study. PGI-C was assessed on a 7-point Likert scale ranged from 1 (greatly improved) to 7 (greatly worsened). Categories were defined based on the PGI-C scores as follows: 1=greatly improved, 2=moderately improved, 3=slightly improved, 4=not changed, 5=slightly worsened, 6=moderately worsened and 7=greatly worsened.

Time frame:
Week 4, 8, 12, 18, 24, 34, 40, and 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48
Percentage of participantsRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mgPlacebo, Ritlecitinib (PF-06651600) 50 mg
Week 4: greatly improved5.434.032.360000
Week 4: moderately improved3.1011.294.727.871.611.591.54
Week 8: greatly improved17.1914.888.134.131.641.591.56
Week 8: moderately improved13.2821.497.3216.534.923.174.69
Week 12: greatly improved22.8322.5813.6012.203.3903.17
Week 12: moderately improved18.1119.3514.4014.633.3910.007.94
Week 18: greatly improved27.6422.3118.0319.331.641.673.28
Week 18: moderately improved23.5823.9727.8715.136.5610.004.92
Week 24: greatly improved36.5126.4528.8028.931.671.544.62
Week 24: moderately improved16.6720.6620.8013.2210.009.233.08
Week 34: greatly improved43.2035.5437.4031.975.0818.647.81
Week 34: moderately improved12.0017.3615.4515.576.7822.0320.31
Week 40: greatly improved43.7534.6837.7030.006.7830.7713.85
Week 40: moderately improved15.6314.5214.7519.1711.8624.6215.38
Week 48: greatly improved44.9633.3342.4031.156.5642.1926.56
Week 48: moderately improved13.1818.7013.6018.039.8417.1917.19
SecondaryChange From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations

AAPPO scale is 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over past week. Items 1-4 assessed current hair loss, eyebrow loss, eyelash loss and body hair loss and were analyzed separately on scale of 0-4, with 0 ='no hair loss' and 4='complete hair loss'. Items 5-8 assessed emotional symptoms. Response choices on these items were scored from 0 ='never' to 4='always'. Items 9-11 assessed activity limitations. Response choices on these items were scored from 0='not at all' to 4='completely'. Change from baseline in AAPPO emotional symptoms sub score were calculated as mean of items 5-8 and ranged from 0(never) to 4(always), where higher scores indicated more emotional symptoms. Change from baseline in AAPPO activity limitations sub score was calculated as mean of items 9-11 and ranged from 0(not at all) to 4(completely), where higher scores indicated more activity limitations. Baseline was defined as pre-dose on Day 1.

Time frame:
Baseline (Day 1), Week 4, 8, 12, 18, and 24
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations
Units on a scaleRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo
Change at Week 4: emotional symptoms-0.37 (-0.49 to -0.25)-0.22 (-0.34 to -0.10)-0.33 (-0.45 to -0.21)-0.31 (-0.44 to -0.19)-0.29 (-0.47 to -0.11)-0.28 (-0.40 to -0.16)
Change at Week 8: emotional symptoms-0.50 (-0.62 to -0.38)-0.46 (-0.58 to -0.34)-0.50 (-0.62 to -0.37)-0.36 (-0.48 to -0.23)-0.45 (-0.62 to -0.27)-0.39 (-0.51 to -0.27)
Change at Week 12: emotional symptoms-0.53 (-0.66 to -0.40)-0.54 (-0.67 to -0.41)-0.48 (-0.61 to -0.34)-0.49 (-0.63 to -0.36)-0.50 (-0.69 to -0.31)-0.36 (-0.49 to -0.23)
Change at Week 18: emotional symptoms-0.64 (-0.78 to -0.51)-0.57 (-0.71 to -0.44)-0.60 (-0.74 to -0.46)-0.54 (-0.68 to -0.40)-0.44 (-0.63 to -0.24)-0.43 (-0.56 to -0.29)
Change at Week 24: emotional symptoms-0.61 (-0.75 to -0.46)-0.61 (-0.76 to -0.47)-0.69 (-0.83 to -0.54)-0.58 (-0.72 to -0.43)-0.49 (-0.70 to -0.28)-0.47 (-0.61 to -0.33)
Change at Week 4: activity limitations-0.19 (-0.29 to -0.08)-0.04 (-0.15 to 0.07)-0.16 (-0.27 to -0.05)-0.13 (-0.24 to -0.02)-0.20 (-0.36 to -0.04)-0.18 (-0.29 to -0.07)
Change at Week 8: activity limitations-0.24 (-0.34 to -0.13)-0.25 (-0.36 to -0.14)-0.18 (-0.29 to -0.07)-0.09 (-0.20 to 0.02)-0.21 (-0.37 to -0.05)-0.20 (-0.31 to -0.09)
Change at Week 12: activity limitations-0.27 (-0.38 to -0.17)-0.22 (-0.32 to -0.11)-0.21 (-0.32 to -0.11)-0.24 (-0.35 to -0.13)-0.27 (-0.42 to -0.11)-0.21 (-0.32 to -0.11)
Change at Week 18: activity limitations-0.35 (-0.45 to -0.24)-0.26 (-0.36 to -0.15)-0.23 (-0.34 to -0.12)-0.23 (-0.34 to -0.12)-0.28 (-0.44 to -0.13)-0.26 (-0.36 to -0.15)
Change at Week 24: activity limitations-0.30 (-0.40 to -0.20)-0.30 (-0.40 to -0.20)-0.31 (-0.41 to -0.21)-0.28 (-0.38 to -0.18)-0.31 (-0.45 to -0.16)-0.29 (-0.39 to -0.19)
SecondaryChange From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations

AAPPO scale is 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over past week. Items 1-4 assessed current hair loss, eyebrow loss, eyelash loss and body hair loss and were analyzed separately on scale of 0-4, with 0 ='no hair loss' and 4='complete hair loss'. Items 5-8 assessed emotional symptoms. Response choices on these items were scored from 0 ='never' to 4='always'. Items 9-11 assessed activity limitations. Response choices on these items were scored from 0='not at all' to 4='completely'. Change from baseline in AAPPO emotional symptoms sub score were calculated as mean of items 5-8 and ranged from 0(never) to 4(always), where higher scores indicated more emotional symptoms. Change from baseline in AAPPO activity limitations sub score was calculated as mean of items 9-11 and ranged from 0(not at all) to 4(completely), where higher scores indicated more activity limitations. Baseline was defined as pre-dose on Day 1.

Time frame:
Baseline (Day 1), Week 34, 40, and 48
Reported as:
Mean · Units on a scale
Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations
Units on a scaleRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mgPlacebo, Ritlecitinib (PF-06651600) 50 mg
Change at Week 34: emotional symptoms-0.78 ± 0.95-0.72 ± 1.00-0.72 ± 0.93-0.71 ± 1.06-0.62 ± 0.83-0.77 ± 0.92-0.64 ± 0.91
Change at Week 40: emotional symptoms-0.84 ± 1.04-0.80 ± 1.02-0.81 ± 0.98-0.83 ± 1.11-0.62 ± 0.96-0.83 ± 1.01-0.66 ± 1.00
Change at Week 48: emotional symptoms-0.96 ± 0.99-0.84 ± 1.07-0.85 ± 1.04-0.72 ± 1.15-0.50 ± 0.89-0.98 ± 1.05-0.68 ± 1.03
Change at Week 34: activity limitations-0.37 ± 0.71-0.31 ± 0.78-0.26 ± 0.73-0.37 ± 0.78-0.33 ± 0.76-0.36 ± 0.59-0.42 ± 0.78
Change at Week 40: activity limitations-0.44 ± 0.76-0.33 ± 0.84-0.25 ± 0.68-0.42 ± 0.81-0.23 ± 0.71-0.40 ± 0.66-0.39 ± 0.84
Change at Week 48: activity limitations-0.43 ± 0.79-0.39 ± 0.84-0.29 ± 0.76-0.36 ± 0.85-0.26 ± 0.90-0.44 ± 0.71-0.36 ± 0.81
SecondaryPercentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48

AAPPO scale is a 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over the past week. Items 1-4 were to assess the current hair loss, eyebrow loss, eyelash loss and body hair loss and were analyzed separately on a scale of 0-4, with 0 ='no hair loss' and 4='complete hair loss', where higher scores indicated more hair loss.

Time frame:
Week 4, 8, 12, 18, 24, 34, 40, and 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48
Percentage of participantsRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mgPlacebo, Ritlecitinib (PF-06651600) 50 mg
Week 4: current hair loss on scalp11.38 (5.77 to 16.99)9.76 (4.51 to 15.00)4.17 (0.59 to 7.74)4.84 (1.06 to 8.62)1.69 (0.00 to 4.99)6.35 (0.33 to 12.37)3.17 (0.00 to 7.50)
Week 8: current hair loss on scalp11.48 (5.82 to 17.13)16.67 (10.00 to 23.33)7.76 (2.89 to 12.63)8.47 (3.45 to 13.50)1.72 (0.00 to 5.07)4.76 (0.00 to 10.02)8.06 (1.29 to 14.84)
Week 12: current hair loss on scalp20.66 (13.45 to 27.88)19.51 (12.51 to 26.52)12.71 (6.70 to 18.72)13.33 (7.25 to 19.42)3.57 (0.00 to 8.43)6.67 (0.35 to 12.98)4.92 (0.00 to 10.34)
Week 18: current hair loss on scalp27.35 (19.27 to 35.43)25.00 (17.25 to 32.75)13.79 (7.52 to 20.07)16.38 (9.64 to 23.11)8.62 (1.40 to 15.84)8.33 (1.34 to 15.33)6.78 (0.36 to 13.19)
Week 24: current hair loss on scalp35.83 (27.25 to 44.41)30.00 (21.80 to 38.20)26.27 (18.33 to 34.21)24.58 (16.81 to 32.34)5.26 (0.00 to 11.06)10.77 (3.23 to 18.31)6.35 (0.33 to 12.37)
Week 34: current hair loss on scalp42.02 (33.15 to 50.89)34.45 (25.92 to 42.99)29.31 (21.03 to 37.59)30.25 (22.00 to 38.51)7.14 (0.40 to 13.89)22.03 (11.46 to 32.61)11.29 (3.41 to 19.17)
Week 40: current hair loss on scalp41.80 (33.05 to 50.56)36.59 (28.07 to 45.10)35.65 (26.90 to 44.41)32.48 (23.99 to 40.96)8.93 (1.46 to 16.40)29.23 (18.17 to 40.29)19.05 (9.35 to 28.74)
Week 48: current hair loss on scalp42.28 (33.55 to 51.01)33.61 (25.22 to 41.99)42.37 (33.46 to 51.29)32.77 (24.34 to 41.21)8.62 (1.40 to 15.84)33.85 (22.34 to 45.35)20.97 (10.83 to 31.10)
Week 4: current hair loss on eyebrows9.09 (3.43 to 14.75)7.14 (2.04 to 12.24)7.45 (2.14 to 12.75)4.17 (0.17 to 8.16)4.35 (0.00 to 10.24)6.25 (0.00 to 13.10)8.70 (0.55 to 16.84)
Week 8: current hair loss on eyebrows17.35 (9.85 to 24.84)21.05 (12.85 to 29.25)11.96 (5.33 to 18.59)10.99 (4.56 to 17.41)6.52 (0.00 to 13.66)4.17 (0.00 to 9.82)11.11 (1.93 to 20.29)
Week 12: current hair loss on eyebrows27.84 (18.92 to 36.75)27.84 (18.92 to 36.75)18.09 (10.30 to 25.87)15.96 (8.55 to 23.36)11.63 (2.05 to 21.21)11.11 (1.93 to 20.29)6.82 (0.00 to 14.27)
Week 18: current hair loss on eyebrows27.66 (18.62 to 36.70)33.68 (24.18 to 43.19)27.47 (18.30 to 36.64)19.78 (11.60 to 27.96)13.33 (3.40 to 23.27)11.11 (1.93 to 20.29)7.14 (0.00 to 14.93)
Week 24: current hair loss on eyebrows32.29 (22.94 to 41.65)32.98 (23.47 to 42.48)30.43 (21.03 to 39.84)29.35 (20.04 to 38.65)6.82 (0.00 to 14.27)12.00 (2.99 to 21.01)10.87 (1.87 to 19.86)
Week 34: current hair loss on eyebrows42.71 (32.81 to 52.60)38.71 (28.81 to 48.61)38.89 (28.82 to 48.96)31.91 (22.49 to 41.34)16.28 (5.24 to 27.31)22.73 (10.34 to 35.11)13.33 (3.40 to 23.27)
Week 40: current hair loss on eyebrows42.27 (32.44 to 52.10)36.84 (27.14 to 46.54)38.89 (28.82 to 48.96)38.04 (28.12 to 47.96)20.00 (8.31 to 31.69)32.00 (19.07 to 44.93)23.91 (11.59 to 36.24)
Week 48: current hair loss on eyebrows44.90 (35.05 to 54.75)34.04 (24.46 to 43.62)43.96 (33.76 to 54.15)39.36 (29.49 to 49.24)15.56 (4.97 to 26.14)38.00 (24.55 to 51.45)33.33 (19.56 to 47.11)
Week 4: current hair loss on eyelashes11.49 (4.79 to 18.20)4.60 (0.20 to 9.00)7.59 (1.75 to 13.44)9.30 (3.16 to 15.44)5.26 (0.00 to 12.36)8.89 (0.57 to 17.20)5.26 (0.00 to 12.36)
Week 8: current hair loss on eyelashes17.44 (9.42 to 25.46)17.65 (9.54 to 25.75)12.82 (5.40 to 20.24)14.81 (7.08 to 22.55)7.89 (0.00 to 16.47)6.67 (0.00 to 13.95)8.11 (0.00 to 16.90)
Week 12: current hair loss on eyelashes29.41 (19.73 to 39.10)26.74 (17.39 to 36.10)16.46 (8.28 to 24.63)19.05 (10.65 to 27.44)8.33 (0.00 to 17.36)14.63 (3.82 to 25.45)8.33 (0.00 to 17.36)
Week 18: current hair loss on eyelashes31.33 (21.35 to 41.30)37.65 (27.35 to 47.95)21.05 (11.89 to 30.22)22.22 (13.17 to 31.28)7.89 (0.00 to 16.47)12.20 (2.18 to 22.21)2.94 (0.00 to 8.62)
Week 24: current hair loss on eyelashes31.40 (21.59 to 41.20)42.17 (31.54 to 52.79)31.17 (20.82 to 41.51)28.05 (18.33 to 37.77)8.33 (0.00 to 17.36)13.04 (3.31 to 22.78)2.63 (0.00 to 7.72)
Week 34: current hair loss on eyelashes40.00 (29.59 to 50.41)36.59 (26.16 to 47.01)37.33 (26.39 to 48.28)34.52 (24.36 to 44.69)11.43 (0.89 to 21.97)21.43 (9.02 to 33.84)13.51 (2.50 to 24.53)
Week 40: current hair loss on eyelashes43.02 (32.56 to 53.49)39.29 (28.84 to 49.73)32.89 (22.33 to 43.46)36.59 (26.16 to 47.01)10.81 (0.81 to 20.82)28.26 (15.25 to 41.27)13.16 (2.41 to 23.91)
Week 48: current hair loss on eyelashes41.86 (31.43 to 52.29)37.35 (26.94 to 47.76)38.16 (27.24 to 49.08)34.52 (24.36 to 44.69)8.11 (0.00 to 16.90)39.13 (25.03 to 53.23)28.95 (14.53 to 43.37)
Week 4: current hair loss on body11.46 (5.09 to 17.83)9.28 (3.50 to 15.05)10.42 (4.31 to 16.53)6.38 (1.44 to 11.32)2.13 (0.00 to 6.25)4.26 (0.00 to 10.03)11.36 (1.99 to 20.74)
Week 8: current hair loss on body14.74 (7.61 to 21.86)15.96 (8.55 to 23.36)13.98 (6.93 to 21.03)10.11 (3.85 to 16.38)2.17 (0.00 to 6.39)6.38 (0.00 to 13.37)11.63 (2.05 to 21.21)
Week 12: current hair loss on body17.02 (9.42 to 24.62)19.15 (11.19 to 27.10)14.89 (7.70 to 22.09)14.29 (7.10 to 21.48)4.44 (0.00 to 10.47)11.36 (1.99 to 20.74)7.14 (0.00 to 14.93)
Week 18: current hair loss on body19.78 (11.60 to 27.96)25.00 (16.15 to 33.85)15.05 (7.79 to 22.32)15.91 (8.27 to 23.55)10.64 (1.82 to 19.45)9.09 (0.60 to 17.59)7.50 (0.00 to 15.66)
Week 24: current hair loss on body25.81 (16.91 to 34.70)27.96 (18.84 to 37.08)20.43 (12.24 to 28.62)22.22 (13.63 to 30.81)6.67 (0.00 to 13.95)16.33 (5.98 to 26.68)11.36 (1.99 to 20.74)
Week 34: current hair loss on body33.33 (23.75 to 42.91)33.70 (24.04 to 43.35)31.52 (22.03 to 41.02)26.09 (17.11 to 35.06)11.36 (1.99 to 20.74)22.73 (10.34 to 35.11)9.30 (0.62 to 17.98)
Week 40: current hair loss on body35.11 (25.46 to 44.76)36.17 (26.46 to 45.88)30.77 (21.29 to 40.25)25.56 (16.54 to 34.57)8.70 (0.55 to 16.84)22.45 (10.77 to 34.13)11.36 (1.99 to 20.74)
Week 48: current hair loss on body34.74 (25.16 to 44.31)34.41 (24.75 to 44.06)36.56 (26.77 to 46.35)30.43 (21.03 to 39.84)10.87 (1.87 to 19.86)34.69 (21.37 to 48.02)20.45 (8.54 to 32.37)
Other pre-specifiedChange From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24

HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for depression subscale; higher score indicating greater severity of depression symptoms. Baseline was defined as pre-dose on Day 1.

Time frame:
Baseline (Day 1), Week 4, 8, 12, and 24
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24
Units on a scaleRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo
Change at Week 4-0.1 (-0.54 to 0.26)-0.4 (-0.82 to -0.01)-0.1 (-0.48 to 0.33)-0.1 (-0.48 to 0.33)-0.3 (-0.86 to 0.32)-0.3 (-0.73 to 0.07)
Change at Week 8-0.5 (-0.89 to -0.06)-0.3 (-0.71 to 0.12)-0.2 (-0.58 to 0.26)0.2 (-0.25 to 0.59)-0.2 (-0.79 to 0.43)-0.3 (-0.73 to 0.10)
Change at Week 12-0.6 (-1.04 to -0.21)-0.4 (-0.81 to 0.03)0.0 (-0.45 to 0.39)0.1 (-0.32 to 0.53)-0.5 (-1.07 to 0.15)-0.1 (-0.53 to 0.30)
Change at Week 24-0.4 (-0.79 to 0.07)-0.8 (-1.21 to -0.35)-0.3 (-0.70 to 0.16)-0.2 (-0.66 to 0.21)-0.4 (-1.04 to 0.21)0.0 (-0.46 to 0.39)
Other pre-specifiedChange From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48

HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for depression subscale; higher score indicating greater severity of depression symptoms. Baseline was defined as pre-dose on Day 1.

Time frame:
Baseline (Day 1), Week 48
Reported as:
Mean · Units on a scale
Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48
Units on a scaleRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mgPlacebo, Ritlecitinib (PF-06651600) 50 mg
Baseline2.7 ± 2.603.0 ± 3.162.9 ± 3.002.8 ± 2.992.8 ± 2.803.2 ± 3.363.3 ± 3.54
Change at Week 48-0.7 ± 2.13-0.4 ± 3.15-0.3 ± 2.67-0.6 ± 2.44-0.5 ± 2.53-0.9 ± 3.25-0.4 ± 3.28
Other pre-specifiedChange From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24

HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for anxiety subscale; higher score indicating greater severity of anxiety symptoms. Baseline was defined as pre-dose on Day 1.

Time frame:
Baseline (Day 1), Week 4, 8, 12, and 24
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24
Units on a scaleRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo
Change at Week 4-0.3 (-0.78 to 0.08)-0.4 (-0.79 to 0.08)-0.4 (-0.79 to 0.08)-0.5 (-0.97 to -0.10)-0.6 (-1.25 to 0.02)-0.1 (-0.54 to 0.32)
Change at Week 8-0.8 (-1.25 to -0.31)-0.4 (-0.88 to 0.07)-0.8 (-1.27 to -0.31)-0.3 (-0.79 to 0.17)-0.9 (-1.59 to -0.20)-0.5 (-0.96 to -0.03)
Change at Week 12-0.7 (-1.22 to -0.28)-0.9 (-1.40 to -0.46)-0.7 (-1.22 to -0.27)-0.3 (-0.77 to 0.19)-0.9 (-1.55 to -0.17)-0.4 (-0.84 to 0.09)
Change at Week 24-0.8 (-1.26 to -0.25)-0.7 (-1.19 to -0.18)-0.8 (-1.28 to -0.27)-0.3 (-0.76 to 0.26)-1.0 (-1.69 to -0.21)-0.6 (-1.06 to -0.07)
Other pre-specifiedChange From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48

HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for anxiety subscale; higher score indicating greater severity of anxiety symptoms. Baseline was defined as pre-dose on Day 1.

Time frame:
Baseline (Day 1), Week 48
Reported as:
Mean · Units on a scale
Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48
Units on a scaleRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mgPlacebo, Ritlecitinib (PF-06651600) 50 mg
Baseline4.6 ± 3.844.5 ± 3.184.9 ± 3.314.3 ± 3.425.2 ± 3.385.3 ± 4.205.3 ± 3.70
Change at Week 48-1.0 ± 2.92-0.8 ± 3.10-0.8 ± 3.09-0.5 ± 3.40-1.2 ± 2.89-1.3 ± 3.31-0.5 ± 4.53
Other pre-specifiedPercentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48

HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for depression subscale; higher score indicating greater severity of depression symptoms.

Time frame:
Week 4, 8, 12, 24 and 48
Reported as:
Number · Percentage of participants
Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48
Percentage of participantsRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mgPlacebo, Ritlecitinib (PF-06651600) 50 mg
Week 442.86 (6.20 to 79.52)60.00 (29.64 to 90.36)53.85 (26.75 to 80.95)42.86 (16.93 to 68.78)40.00 (0.00 to 82.94)60.00 (17.06 to 100.00)50.00 (19.01 to 80.99)
Week 866.67 (28.95 to 100.00)45.45 (16.03 to 74.88)58.33 (30.44 to 86.23)33.33 (6.66 to 60.01)20.00 (0.00 to 55.06)50.00 (1.00 to 99.00)40.00 (9.64 to 70.36)
Week 1250.00 (9.99 to 90.01)63.64 (35.21 to 92.06)66.67 (39.99 to 93.34)30.77 (5.68 to 55.86)20.00 (0.00 to 55.06)60.00 (17.06 to 100.00)62.50 (28.95 to 96.05)
Week 2471.43 (37.96 to 100.00)63.64 (35.21 to 92.06)41.67 (13.77 to 69.56)42.86 (16.93 to 68.78)50.00 (1.00 to 99.00)50.00 (1.00 to 99.00)50.00 (19.01 to 80.99)
Week 4850.00 (9.99 to 90.01)63.64 (35.21 to 92.06)58.33 (30.44 to 86.23)46.15 (19.05 to 73.25)80.00 (44.94 to 100.00)60.00 (17.06 to 100.00)60.00 (29.64 to 90.36)
Other pre-specifiedPercentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48

HADS is a validated 14-item PRO measure used to assessed states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for anxiety subscale; higher score indicating greater severity of anxiety symptoms.

Time frame:
Week 4, 8, 12, 24 and 48
Reported as:
Number · Percentage of participants
Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48
Percentage of participantsRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mgPlacebo, Ritlecitinib (PF-06651600) 50 mg
Week 451.72 (33.54 to 69.91)45.45 (24.65 to 66.26)34.62 (16.33 to 52.90)37.50 (13.78 to 61.22)40.00 (15.21 to 64.79)31.58 (10.68 to 52.48)30.77 (5.68 to 55.86)
Week 846.43 (27.96 to 64.90)50.00 (28.09 to 71.91)68.00 (49.71 to 86.29)41.67 (13.77 to 69.56)71.43 (47.76 to 95.09)33.33 (11.56 to 55.11)46.15 (19.05 to 73.25)
Week 1250.00 (31.48 to 68.52)57.89 (35.69 to 80.10)38.46 (19.76 to 57.16)56.25 (31.94 to 80.56)42.86 (16.93 to 68.78)47.37 (24.92 to 69.82)41.67 (13.77 to 69.56)
Week 2451.85 (33.01 to 70.70)65.00 (44.10 to 85.90)50.00 (30.78 to 69.22)46.67 (21.42 to 71.91)57.14 (31.22 to 83.07)44.44 (21.49 to 67.40)38.46 (12.02 to 64.91)
Week 4853.85 (34.68 to 73.01)66.67 (44.89 to 88.44)60.00 (40.80 to 79.20)50.00 (23.81 to 76.19)61.54 (35.09 to 87.98)57.89 (35.69 to 80.10)58.33 (30.44 to 86.23)

Adverse events

Collected over Baseline up to 5 weeks after last dose of study drug (maximum up to Week 53). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ritlecitinib (PF-06651600) 200 mg Then 50 mg0/131 (0%)4/131 (3.1%)84/131 (64.1%)
Ritlecitinib (PF-06651600) 200 mg Then 30 mg0/129 (0%)2/129 (1.6%)76/129 (58.9%)
Ritlecitinib (PF-06651600) 50 mg0/130 (0%)2/130 (1.5%)81/130 (62.3%)
Ritlecitinib (PF-06651600) 30 mg0/132 (0%)1/132 (0.8%)77/132 (58.3%)
Ritlecitinib (PF-06651600) 10 mg0/62 (0%)2/62 (3.2%)32/62 (51.6%)
Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg0/65 (0%)0/65 (0%)39/65 (60%)
Placebo, Ritlecitinib (PF-06651600) 50 mg0/66 (0%)3/66 (4.5%)39/66 (59.1%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mgPlacebo, Ritlecitinib (PF-06651600) 50 mg
Suicidal behaviourPsychiatric disorders0/1311/1290/1300/1321/620/650/66
EczemaSkin and subcutaneous tissue disorders0/1310/1290/1300/1321/620/650/66
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/1310/1290/1300/1320/620/651/66
Conversion disorderPsychiatric disorders0/1310/1290/1300/1320/620/651/66
Heavy menstrual bleedingReproductive system and breast disorders0/1310/1290/1300/1320/620/651/66
AppendicitisInfections and infestations1/1311/1290/1300/1320/620/650/66
Chemical poisoningInjury, poisoning and procedural complications0/1311/1290/1300/1320/620/650/66
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1310/1291/1300/1320/620/650/66
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/1310/1291/1300/1320/620/650/66
EmpyemaInfections and infestations1/1310/1290/1300/1320/620/650/66
Most frequent other events
Showing 10 of 23
Most frequent other events
EventRitlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mgPlacebo, Ritlecitinib (PF-06651600) 50 mg
HeadacheNervous system disorders17/13114/12916/13024/13212/628/658/66
NasopharyngitisInfections and infestations19/13121/12918/13021/1327/627/654/66
Upper respiratory tract infectionInfections and infestations18/13112/12911/13016/1322/627/656/66
NauseaGastrointestinal disorders11/1313/1293/13012/1323/628/651/66
AcneSkin and subcutaneous tissue disorders6/13110/12912/13012/1323/625/658/66
MyalgiaMusculoskeletal and connective tissue disorders6/1313/1293/1305/1326/620/651/66
DiarrhoeaGastrointestinal disorders9/1314/12912/1308/1320/624/651/66
ArthralgiaMusculoskeletal and connective tissue disorders4/1315/1292/1304/1322/622/656/66
FolliculitisInfections and infestations11/13111/1298/1305/1324/624/654/66
Urinary tract infectionInfections and infestations11/1313/1291/1305/1320/624/652/66

Baseline characteristics

Full analysis set (FAS) included all participants who were randomized, regardless of whether they received study medication.

Age, Continuous
Age, Continuous(Years)Ritlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mgPlacebo, Ritlecitinib (PF-06651600) 50 mgTotal
Mean34.5 ± 14.9833.7 ± 13.7532.4 ± 13.3633.7 ± 14.8334.3 ± 13.8833.0 ± 14.0135.0 ± 15.8933.8 ± 14.33
Sex: Female, Male
Sex: Female, Male(Participants)Ritlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mgPlacebo, Ritlecitinib (PF-06651600) 50 mgTotal
Female81857180434640446
Male51455952201926272
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ritlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mgPlacebo, Ritlecitinib (PF-06651600) 50 mgTotal
Hispanic or Latino1816112387487
Not Hispanic or Latino113114116109555861626
Unknown or Not Reported10300015
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ritlecitinib (PF-06651600) 200 mg Then 50 mgRitlecitinib (PF-06651600) 200 mg Then 30 mgRitlecitinib (PF-06651600) 50 mgRitlecitinib (PF-06651600) 30 mgRitlecitinib (PF-06651600) 10 mgPlacebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mgPlacebo, Ritlecitinib (PF-06651600) 50 mgTotal
American Indian or Alaska Native01020003
Asian33284334171417186
Native Hawaiian or Other Pacific Islander00001001
Black or African American675322227
White92907991424747488
More than one race03120208
Unknown or Not Reported11201005
08

Study locations

155 sites
  • The University of Alabama at Birmingham Hospital Outreach Lab
    Birmingham, Alabama 35233, United States
  • The University of Alabama at Birmingham, Department of Dermatology
    Birmingham, Alabama 35233, United States
  • The University of Alabama at Birmingham, Department of Dermatology
    Birmingham, Alabama 35294, United States
  • Mosaic Dermatology
    Beverly Hills, California 90211, United States
  • University of California, Irvine, Department of Dermatology, Dermatology Clinical Research Center
    Irvine, California 92697, United States
  • Dermatology Specialists, Inc.
    Murrieta, California 92562, United States
  • University of California, San Francisco
    San Francisco, California 94115, United States
  • Kaiser Permanente Clinical Trials Unit
    San Francisco, California 94118, United States
  • Southern California Dermatology, Inc.
    Santa Ana, California 92701, United States
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital Clinical and Translational Research Center
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital Outpatient Pavillion
    Aurora, Colorado 80045, United States
  • Yale School of Medicine
    New Haven, Connecticut 06510, United States
  • Church Street Research Unit
    New Haven, Connecticut 06519, United States
  • Medstar Georgetown University Hospital Center-Department of Otolaryngology
    Washington, District of Columbia 20007, United States
  • Medstar Washington Hospital Center-Claude Nogay Research Pharmacy
    Washington, District of Columbia 20010, United States
  • Medstar Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • Medstar Georgetown University Hospital Center-Department of Pediatrics
    Washington, District of Columbia 20016, United States
  • Siperstein Dermatology Group
    Boynton Beach, Florida 33472, United States
  • Park Avenue Dermatology
    Orange Park, Florida 32073, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • Advanced Clinical Research
    Meridian, Idaho 83642, United States
  • Northwestern Medical Group
    Chicago, Illinois 60611, United States
  • Northwestern Medicine Diagnostic Testing Center
    Chicago, Illinois 60611, United States
  • Northwestern Medicine
    Chicago, Illinois 60611, United States
  • Northwestern Memorial Hospital, Investigational Research Pharmacy
    Chicago, Illinois 60611, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • NorthShore University HealthSystem
    Skokie, Illinois 60077, United States
  • Southern Illinois University School of Medicine
    Springfield, Illinois 62702, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • University of Iowa Hospitals and Clinics; Department of Pharmacy-IDS;
    Iowa City, Iowa 52242, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Medstar Georgetown University Hospital - Department of Dermatology
    Chevy Chase, Maryland 20815, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • University of Minnesota Department of Dermatology
    Minneapolis, Minnesota 55455, United States
  • University of Minnesota Medical Center, Investigational Drug Services Attn: Darlette Luke
    Minneapolis, Minnesota 55455, United States
  • Skin Specialists, PC
    Omaha, Nebraska 68144, United States
  • The Dermatology Group, P.C.
    Verona, New Jersey 07044, United States
  • NYU School of Medicine, The Ronald O. Perelman Department of Dermatology
    New York, New York 10016, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • UNC CTRC
    Chapel Hill, North Carolina 27514, United States
  • UNC Hospitals, Investigational Drug Service
    Chapel Hill, North Carolina 27514, United States
  • UNC Dermatology Clinical Trials Unit
    Chapel Hill, North Carolina 27516, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Vital Prospects Clinical Research Institute, P.C
    Tulsa, Oklahoma 74136, United States
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • CINME Centro de Investigaciones Metabolicas
    Caba, Buenos Aires C1027AAP, Argentina
  • Psoriahue Medicina Interdisciplinaria
    Caba, C1425DKG, Argentina
  • Premier Specialists Pty Ltd
    Kogarah, New South Wales 2217, Australia
  • St George Dermatology and Skin Cancer Centre
    Kogarah, New South Wales 2217, Australia
  • The Skin Centre
    Benowa, Queensland 4217, Australia
  • Veracity Clinical Research Pty Ltd
    Woolloongabba, Queensland 4102, Australia
  • Skin Health Institute
    Carlton, Victoria 3053, Australia
  • Sinclair Dermatology
    East Melbourne, Victoria 3002, Australia
  • The Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Royal Park Campus
    Parkville, Victoria 3052, Australia
  • Wiseman Dermatology Research Inc.
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Eastern Canada Cutaneous Research Associates Ltd.
    Halifax, Nova Scotia B3H 1Z2, Canada
  • Guenther Research Inc
    London, Ontario N6A 3H7, Canada
  • Lynderm Research Inc.
    Markham, Ontario L3P 1X3, Canada
  • The Centre for Clinical Trials
    Oakville, Ontario L6J 7W5, Canada
  • SKiN Centre for Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • York Dermatology Clinic and Research Centre
    Richmond Hill, Ontario L4C 9M7, Canada
  • Medicor Research Inc
    Sudbury, Ontario P3A1W8, Canada
  • Sudbury Skin Clinique
    Sudbury, Ontario P3C 1X8, Canada
  • Research Toronto
    Toronto, Ontario M4W 2N4, Canada
  • Innovaderm Research Inc.
    Montreal, Quebec H2X 2V1, Canada
  • Centre de Recherche Dermatologique du Quebec metropolitain
    Quebec, G1V 4X7, Canada
  • Centro Internacional de Estudios Clinicos, CIEC
    Santiago, Recoleta 8420383, Chile
  • Centro Medico Skin Med
    Santiago, Región Metropolitana 7580206, Chile
  • Clinica Dermacross S.A.
    Santiago, Región Metropolitana 7640881, Chile
  • Medical Skin Center
    Vina del Mar, Valparaiso 2530900, Chile
  • Peking University First Hospital
    Beijing, Beijing 100034, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing 100050, China
  • Peking University Third Hospital
    Beijing, Beijing 100191, China
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510080, China
  • The University of Hong Kong - Shenzhen Hospital
    Shenzhen, Guangdong 518053, China
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • The First Affiliated Hospital with Nanjing Medical University
    Nanjing, Jiangsu 210029, China
  • Huashan Hospital, Fudan University/Dermatology Department
    Shanghai, Shanghai 200040, China
  • The First Affiliated Hospital of College of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310003, China
  • The Second Affiliated Hospital of College of Medicine, Zhejiang University/Dermatology Dept
    Hangzhou, Zhejiang 310009, China
  • Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
    Shanghai, 200025, China
  • Fundacion Centro de Investigacion Clinica CIC
    Medellin, Antioquia 050001, Colombia
  • Fundacion Hospitalaria San Vicente de Paul
    Medellin, Antioquia 050010, Colombia
  • Centro de Investigación en Reumatología y Especialidades Médicas SAS - CIREEM SAS
    Bogota, D.c. 110221, Colombia
  • DERMAMEDICA s.r.o.
    Nachod, 54701, Czechia
  • Fakultni nemocnice Olomouc
    Olomouc, 779 00, Czechia
  • Clintrial s.r.o.
    Praha 10, 100 00, Czechia
  • Sanatorium profesora Arenbergera
    Praha 1, 11000, Czechia
  • Nemocnice Na Bulovce
    Praha 8- Liben, 180 81, Czechia
  • Fachklinik Bad Bentheim
    Bad Bentheim, 48455, Germany
  • Emovis GmbH
    Berlin, 10629, Germany
  • Universitaetsklinikum Erlangen
    Erlangen, 91054, Germany
  • University Hospital Frankfurt
    Frankfurt am Main, 60590, Germany
  • University Hospital Schleswig-Holstein
    Luebeck, 23538, Germany
  • University Hospital Muenster
    Muenster, 48149, Germany
  • Semmelweis Egyetem
    Budapest, 1085, Hungary
  • Debreceni Egyetem
    Debrecen, 4032, Hungary
  • Bugat Pal Korhaz, Borgyogyaszat
    Gyongyos, 3200, Hungary

Showing the first 100 of 155 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Dec 2020, 24 months.

Results were first posted in Feb 2022, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2018
First posted
Nov 7, 2018
StartActual
Dec 3, 2018
Primary completionActual
Dec 31, 2020
CompletionActual
Jun 24, 2021
Results first posted
Feb 24, 2022
Last update
Feb 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03732807
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 7, 2018
Start date
Dec 3, 2018
Primary completion
Dec 31, 2020
Completion
Jun 24, 2021
Results posted
Feb 24, 2022
Last update
Feb 24, 2022

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06651600

Start the discussion